← Home
🚀 Sign up Free for Company Insights & Valuation!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free
Ipsen
-4.64%
Pharma / Pharmaceuticals, Biotechnology
At a Glance | Core Facts | Company Due Diligence | Industry Due Diligence | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | WebOverview
Ipsen is a French pharmaceutical company that specializes in the development and manufacture of medicines for rare diseases and specialty healthcare. The company was founded in 1929 by Henri Beaufour and is headquartered in Boulogne-Billancourt, France.
Ipsen's main focus is on areas such as oncology, neuroscience, and rare diseases. They have a strong global presence with products marketed in 115 countries and around 5,700 employees worldwide.
The company's goal is to improve the quality of life for patients with rare or debilitating diseases through their innovative treatments. They invest heavily in research and development, with approximately 20% of their sales revenues reinvested in this area.
Ipsen has a diverse portfolio of products including medications for conditions such as neuroendocrine tumors, spasticity, and gastrointestinal disorders. They also have a strong commitment to sustainability and ethical practices, with a focus on social responsibility and environmental protection.
In addition to their pharmaceutical business, Ipsen also has a presence in consumer healthcare with their Vichy, La Roche-Posay, and Dysport skin and beauty brands.
In recent years, Ipsen has expanded its international presence through strategic partnerships and acquisitions, including a joint venture with Teijin Pharma in Japan and the acquisition of Clementia Pharmaceuticals in Canada.
Overall, Ipsen continues to be a major player in the pharmaceutical industry, dedicated to providing life-changing treatments for patients around the world.
Ipsen's main focus is on areas such as oncology, neuroscience, and rare diseases. They have a strong global presence with products marketed in 115 countries and around 5,700 employees worldwide.
The company's goal is to improve the quality of life for patients with rare or debilitating diseases through their innovative treatments. They invest heavily in research and development, with approximately 20% of their sales revenues reinvested in this area.
Ipsen has a diverse portfolio of products including medications for conditions such as neuroendocrine tumors, spasticity, and gastrointestinal disorders. They also have a strong commitment to sustainability and ethical practices, with a focus on social responsibility and environmental protection.
In addition to their pharmaceutical business, Ipsen also has a presence in consumer healthcare with their Vichy, La Roche-Posay, and Dysport skin and beauty brands.
In recent years, Ipsen has expanded its international presence through strategic partnerships and acquisitions, including a joint venture with Teijin Pharma in Japan and the acquisition of Clementia Pharmaceuticals in Canada.
Overall, Ipsen continues to be a major player in the pharmaceutical industry, dedicated to providing life-changing treatments for patients around the world.
What is special about the company?
1. History of Innovation: The Ipsen company has a rich history of innovation and has been at the forefront of developing new and advanced pharmaceutical products for over 90 years. They have a track record of pioneering new treatments for various diseases and have made a significant impact on the medical industry.
2. Global Presence: Ipsen has a global presence, with operations in more than 30 countries and commercial activities in over 115 countries. This allows them to reach a large patient population and bring their treatments to a wide range of markets.
3. Focus on Rare Diseases: Ipsen has a strong focus on rare and niche diseases, with a dedicated Rare Diseases unit that works towards developing treatments for diseases that affect a small number of people. This commitment to rare diseases has led to significant advancements in treatment options for these conditions.
4. Patient-Centered Approach: Ipsen has a patient-centered approach, focusing on understanding the needs and concerns of patients to develop treatments that best meet their requirements. They also actively engage with patient advocacy groups to raise awareness and support for rare diseases.
5. Strong R&D Pipeline: Ipsen has a robust and diverse R&D pipeline, with a focus on developing new and innovative treatments in areas such as oncology, neuroscience, and rare diseases. This pipeline reflects the company's commitment to continuous innovation and growth.
6. Sustainability: Ipsen is committed to sustainable development and takes measures to minimize its environmental impact and promote responsible practices. This includes reducing their carbon footprint, improving energy efficiency, and promoting diversity and inclusion within their workforce.
7. Corporate Social Responsibility: Ipsen is dedicated to supporting communities and giving back to society through various social responsibility programs. This includes initiatives to improve access to healthcare in underserved communities, supporting healthcare professionals, and raising awareness about rare diseases.
8. Strong Culture: Ipsen has a strong culture that values collaboration, integrity, and commitment to excellence. Their employees are motivated to make a positive impact in the world and are encouraged to bring their unique perspectives and expertise to their work.
9. Awards and Recognitions: Ipsen has been recognized for its contributions in the pharmaceutical industry with numerous awards and accolades. These include the "Best Employer Brand" award by the World HRD Congress and being named one of the "Most Ethical Companies" by the Ethisphere Institute.
10. Strategic Partnerships: Ipsen has formed strategic partnerships with other pharmaceutical companies and research institutions to advance their R&D efforts and bring innovative treatments to market faster. This collaboration allows for the sharing of knowledge and resources, ultimately benefiting patients and healthcare providers.
2. Global Presence: Ipsen has a global presence, with operations in more than 30 countries and commercial activities in over 115 countries. This allows them to reach a large patient population and bring their treatments to a wide range of markets.
3. Focus on Rare Diseases: Ipsen has a strong focus on rare and niche diseases, with a dedicated Rare Diseases unit that works towards developing treatments for diseases that affect a small number of people. This commitment to rare diseases has led to significant advancements in treatment options for these conditions.
4. Patient-Centered Approach: Ipsen has a patient-centered approach, focusing on understanding the needs and concerns of patients to develop treatments that best meet their requirements. They also actively engage with patient advocacy groups to raise awareness and support for rare diseases.
5. Strong R&D Pipeline: Ipsen has a robust and diverse R&D pipeline, with a focus on developing new and innovative treatments in areas such as oncology, neuroscience, and rare diseases. This pipeline reflects the company's commitment to continuous innovation and growth.
6. Sustainability: Ipsen is committed to sustainable development and takes measures to minimize its environmental impact and promote responsible practices. This includes reducing their carbon footprint, improving energy efficiency, and promoting diversity and inclusion within their workforce.
7. Corporate Social Responsibility: Ipsen is dedicated to supporting communities and giving back to society through various social responsibility programs. This includes initiatives to improve access to healthcare in underserved communities, supporting healthcare professionals, and raising awareness about rare diseases.
8. Strong Culture: Ipsen has a strong culture that values collaboration, integrity, and commitment to excellence. Their employees are motivated to make a positive impact in the world and are encouraged to bring their unique perspectives and expertise to their work.
9. Awards and Recognitions: Ipsen has been recognized for its contributions in the pharmaceutical industry with numerous awards and accolades. These include the "Best Employer Brand" award by the World HRD Congress and being named one of the "Most Ethical Companies" by the Ethisphere Institute.
10. Strategic Partnerships: Ipsen has formed strategic partnerships with other pharmaceutical companies and research institutions to advance their R&D efforts and bring innovative treatments to market faster. This collaboration allows for the sharing of knowledge and resources, ultimately benefiting patients and healthcare providers.
What the company's business model?
The Ipsen company is a global biopharmaceutical company that focuses on developing and commercializing innovative products for patients with serious diseases. Their business model is centered around three key elements: research and development (R&D), commercialization, and sustainability.
1. Research and Development (R&D):
Ipsen invests heavily in R&D, with an aim to develop novel therapies and treatments for diseases with high unmet medical needs. They have a strong in-house R&D team and also collaborate with academic institutions, biotech companies, and other partners to identify and develop promising drug candidates.
2. Commercialization:
Ipsen has a global commercialization strategy, with a presence in more than 115 countries. They have a diversified portfolio of products in different therapeutic areas such as neurology, endocrinology, and oncology. They use a combination of direct sales, partnerships, and licensing agreements to reach patients in different regions.
3. Sustainability:
As a healthcare company, Ipsen is committed to sustainability and corporate social responsibility. They have a strong ethical code of conduct and are dedicated to promoting access to healthcare for all through various initiatives, including patient assistance programs, disease awareness campaigns, and partnerships with patient organizations.
Overall, Ipsen's business model focuses on developing and commercializing innovative treatments to improve the lives of patients, while also ensuring the sustainability and growth of the company.
1. Research and Development (R&D):
Ipsen invests heavily in R&D, with an aim to develop novel therapies and treatments for diseases with high unmet medical needs. They have a strong in-house R&D team and also collaborate with academic institutions, biotech companies, and other partners to identify and develop promising drug candidates.
2. Commercialization:
Ipsen has a global commercialization strategy, with a presence in more than 115 countries. They have a diversified portfolio of products in different therapeutic areas such as neurology, endocrinology, and oncology. They use a combination of direct sales, partnerships, and licensing agreements to reach patients in different regions.
3. Sustainability:
As a healthcare company, Ipsen is committed to sustainability and corporate social responsibility. They have a strong ethical code of conduct and are dedicated to promoting access to healthcare for all through various initiatives, including patient assistance programs, disease awareness campaigns, and partnerships with patient organizations.
Overall, Ipsen's business model focuses on developing and commercializing innovative treatments to improve the lives of patients, while also ensuring the sustainability and growth of the company.
Interesting facts about the company
- Ipsen is a global biopharmaceutical company specializing in the development and production of medicines for the treatment of rare and serious diseases.
- The company was founded in 1929 by Henri and Jeanne Ipsen in Paris, France.
- Ipsen initially focused on the production of hormones for medical use, but later expanded into other therapeutic areas including endocrinology, neurology, and oncology.
- In 1974, Ipsen was the first European company to launch recombinant human insulin for the treatment of diabetes.
- The company has a strong presence in France, as well as key markets in North America, Europe, and Asia.
- Ipsen is known for its strong commitment to research and development, with approximately 700 million euros invested in R&D annually.
- The company has a global network of research and development centers, with the largest facility located in Les Ulis, France.
- Ipsen has a portfolio of over 20 products, and is continuously expanding its product pipeline through collaborations and partnerships.
- The company has a strong focus on sustainability and corporate social responsibility, with initiatives in place to reduce its environmental impact and promote diversity and inclusion.
- Ipsen has received recognition and awards for its work in rare diseases, including being named one of the Top 100 Most Innovative Companies in the World by Forbes in 2017.
See Company Due Diligence:
- The company was founded in 1929 by Henri and Jeanne Ipsen in Paris, France.
- Ipsen initially focused on the production of hormones for medical use, but later expanded into other therapeutic areas including endocrinology, neurology, and oncology.
- In 1974, Ipsen was the first European company to launch recombinant human insulin for the treatment of diabetes.
- The company has a strong presence in France, as well as key markets in North America, Europe, and Asia.
- Ipsen is known for its strong commitment to research and development, with approximately 700 million euros invested in R&D annually.
- The company has a global network of research and development centers, with the largest facility located in Les Ulis, France.
- Ipsen has a portfolio of over 20 products, and is continuously expanding its product pipeline through collaborations and partnerships.
- The company has a strong focus on sustainability and corporate social responsibility, with initiatives in place to reduce its environmental impact and promote diversity and inclusion.
- Ipsen has received recognition and awards for its work in rare diseases, including being named one of the Top 100 Most Innovative Companies in the World by Forbes in 2017.
See Company Due Diligence:
Wait! There's more — sign up for free or log in